Business
Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants
BERKELEY, Calif. and MAINZ, Germany, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics
About this update from Quantum Cyber N.v.
[{"type":"text","content":"BERKELEY, Calif. and MAINZ, Germany, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced the pricing of a follow-on offering of 2,222,222 units, with each unit consisting of one ordinary share (or pre-funded warrant in lieu thereof) and one Series A warrant to purchase one and one half ordinary shares for gross proceeds of approximately $3.0 million. Each unit is being sold at an effective offering price of $1.35 per unit. Each Series A warrant will be immediately exercisable at an exercise price of $1.35 per share and will expire five years from the date of issuance. Maxim Group LLC is acting as the sole placement agent for the offering. The offering is expected to close on or about August 5, 2025, subject to customary closing conditions. The newly issued securities described above are being offered pursuant to a registration statement on Form F-1, as amended (File No. 333-289095) (the “Registration Statement”), which was declared effective by the Securities and Exchange Commission (the “SEC”) on August 4, 2025. The offering is being made only by means of a prospectus which is a part of the Registration Statement. A final prospectus relating to the offering will be filed with the SEC. Copies of the final prospectus relating to this offering may be obtained from Maxim Group LLC, 300 Park Avenue, 16th Floor, New York, NY 10022, at (212) 895-3745. This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. Please visit Mainz Biomed’s official website for investors at mainzbiomed.com/investors/ for more information About Mainz Biomed NV Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert®, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer. ColoAlert® is marketed across Europe. The Company is currently running a clinica...